Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol
Today. 1999;20(10):469-473.
Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev
Immunol. 2004;4(10):762-774.
Oda S, Sugimoto H, Yoshida T, Shiro Y. Crystallization and preliminary crystallographic studies of human
indoleamine 2,3-dioxygenase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006;62(Pt 3):221-223.
Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R. Antioxidants inhibit indoleamine
2,3-dioxygenase in IFN-γ-activated human macrophages: posttranslational regulation by pyrrolidine
dithiocarbamate. J Immunol. 2001;166(10):6332-6340.
Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.
Cancer Res. 2012;72(21):5435-5440.
Routy JP, Routy B, Graziani GM, Mehraj V. The kynurenine pathway is a double-edged sword in
immune-privileged sites and in cancer: implications for immunotherapy. Int J Tryptophan Res. 2016;9:67-77.
Mbongue JC, Nicholas DA, Torrez TW, Kim N-S, Firek AF, Langridge WHR. The role of indoleamine 2,
3-dioxygenase in immune suppression and autoimmunity. Vaccines (Basel). 2015;3(3):703-729.
Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells
in tumor-draining lymph nodes. J Clin Invest. 2004;114(2):280-290.
Liu P, Xie B-L, Cai S-H, et al. Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma
impairs the cytolytic function of peripheral blood lymphocytes. BMC Cancer. 2009. doi:1186/1471-2407-9-416.
Löb S, Königsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not
dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother. 2009;58(1):153-157.
Chen PW, Mellon JK, Mayhew E, et al. Uveal melanoma expression of indoleamine 2,3-deoxygenase:
establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res. 2007;85(5):617-625.
Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing
indoleamine 2,3-dioxygenase. Science. 2002;297(5588):1867-1870.
Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical
resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389-1402.
Wainwright DA, Balyasnikova IV, Chang AL, et al. IDO expression in brain tumors increases the recruitment
of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18(22):6110-6121.
Folgiero V, Goffredo BM, Filippini P, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia
blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget. 2014;5(8):2052-2064.
Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human
cancers: clinical and immunologic perspectives. Clin Cancer Res. 2011;17(22):6985-6991.
Jia Y, Wang H, Wang Y, et al. Low expression of Bin1, along with high expression of IDO in tumor tissue and
draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J
Cancer. 2015;137(5):1095-1106.
Mangaonkar A, Mondal AK, Fulzule S, et al. A novel immunohistochemical score to predict early mortality in
acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. Sci Rep. 2017;7(1):12892.
doi:10.1038/s41598-017-12940-0.
Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J
Immunother Cancer. 2015;3:51. doi:10.1186/s40425-015-0094-9.
Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on
tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269-1274.
Ladomersky E, Zhai L, Lenzen A, et al. IDO1 inhibition synergizes with radiation and PD-1 blockade to
durably increase survival against advanced glioblastoma. Clin Cancer Res. 2018;24(11):2559-2573.
Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes
directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117(9):2570-2582.